“…Multiple gene therapy approaches, including gene silencing (CMT1A), allele-specific silencing (CMT2E), gene replacement (CMTX1, CMT4A, CMT4C, CMT2A), gene editing with CRISPR-Cas9 (CMT1A, CMT2A, CMT2D-F), and antisense oligonucleotides (CMT1A) are under development. Some approaches, such as small molecules, enzyme replacements, and antioxidants, target common downstream pathways in hereditary neuropathies 94-97 …”